C3 Glomerulopathy Clinical Trial
Official title:
A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)
This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.
The proposed study, NM8074-C3G-101, will enroll a planned number of 18 patients, with the potential to enroll more patients. There will be 3 cohorts with 6 patients each dosed at 5, 10, or 20 mg/kg depending on which cohort they are assigned to. Enrollment in the subsequent higher dose level cohort will occur after the previous cohort has been evaluated for safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03955445 -
Long-term Efficacy, Safety and Tolerability of LNP023 in C3G
|
Phase 3 | |
| Recruiting |
NCT04183101 -
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
|
Phase 2 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Active, not recruiting |
NCT05067127 -
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
| Active, not recruiting |
NCT05809531 -
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
| Recruiting |
NCT06209736 -
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
|
Phase 2 | |
| Terminated |
NCT03459443 -
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
|
Phase 2 | |
| Completed |
NCT03369236 -
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
|
Phase 2 | |
| Active, not recruiting |
NCT04572854 -
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
|
Phase 2 | |
| Recruiting |
NCT02682407 -
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
|
Phase 2 | |
| Recruiting |
NCT05083364 -
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
|
Phase 1 | |
| Completed |
NCT03723512 -
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
|
N/A | |
| Completed |
NCT03124368 -
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
|
Phase 2 | |
| Available |
NCT04729062 -
C3G/Primary IC-MPGN EAP
|